Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 408, Issue 3, 2011, Pages 411-416

  Tang, Zhen Ning ^a   Zhang, Fan ^a   Tang, Peng ^a   Qi, Xiao Wei ^a   Jiang, Jun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Hypoxia; Migration; RANK; RANKL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 79955785090     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.035     Document Type: Article

References (28)

1. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
2. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., G Van, Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., Penninger J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
3. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., Boyle W.J., Khokha R., Penninger J.M. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
4. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., Rabbani S.A. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006, 107:289-298.
5. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J.Q., Hoffman R.M., Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553.
6. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T., Penninger J.M. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
7. Chen L.M., Kuo C.H., Lai T.Y., Lin Y.M., Su C.C., Hsu H.H., Tsai F.J., Tsai C.H., Huang C.Y., Tang C.H. RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J. Cell. Biochem. 2011, 112:933-941.
8. Mori K., Le Goff B., Charrier C., Battaglia S., Heymann D., Redini F. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 2007, 40:981-990.
9. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., Hanada R., Joshi P.A., Aliprantis A., Glimcher L., Pasparakis M., Khokha R., Ormandy C.J., Widschwendter M., Schett G., Penninger J.M. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
10. Srivastava S., Matsuda M., Hou Z., Bailey J.P., Kitazawa R., Herbst M.P., Horseman N.D. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J. Biol. Chem. 2003, 278:46171-46178.
11. Joshi P.A., Jackson H.W., Beristain A.G., Di Grappa M.A., Mote P.A., Clarke C.L., Stingl J., Waterhouse P.D., Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
12. Asselin-Labat M.L., Vaillant F., Sheridan J.M., Pal B., Wu D., Simpson E.R., Yasuda H., Smyth G.K., Martin T.J., Lindeman G.J., Visvader J.E. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802.
13. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007, 67:4157-4163.
14. Gort E.H., Groot A.J., Derks V.D.V.T., van der Groep P., Verlaan I., van Laar T., van Diest P.J., van der Wall E., Shvarts A. Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene 2006, 25:6123-6127.
15. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 2008, 266:12-20.
16. Chen L., Qiu J., Yang C., Yang X., Chen X., Jiang J., Luo X. Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells. Cancer Lett. 2009, 278:210-219.
17. Chen X., Wu X., Zhao Y., Wang G., Feng J., Li Q., Qian G. A novel binding protein of single immunoglobulin IL-1 receptor-related molecule: paralemmin-3. Biochem. Biophys. Res. Commun. 2011, 404:1029-1033.
18. Meng X.N., Jin Y., Yu Y., Bai J., Liu G.Y., Zhu J., Zhao Y.Z., Wang Z., Chen F., Lee K.Y., Fu S.B. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Brit. J. Cancer 2009, 101:327-334.
19. Narducci P., Bareggi R., Nicolin V. Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. Acta Histochem. 2011, 113:73-81.
20. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R., Pinkas J., Branstetter D., Dougall W.C. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
21. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., Gillespie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
22. Mancino A.T., Klimberg V.S., Yamamoto M., Manolagas S.C., Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res. 2001, 100:18-24.
23. Park H.R., Min S.K., Cho H.D., Kim D.H., Shin H.S., Park Y.E. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J. Korean Med. Sci. 2003, 18:541-546.
24. Cross S.S., Harrison R.F., Balasubramanian S.P., Lippitt J.M., Evans C.A., Reed M.W., Holen I. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J. Clin. Pathol. 2006, 59:716-720.
25. Nicolin V., Narducci P. Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem. 2010, 112:189-192.
26. Schofield C.J., Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 2005, 338:617-626.
27. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
28. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 1999, 256:449-455.